|Bid||36.71 x 2700|
|Ask||36.72 x 7000|
|Day's Range||36.27 - 36.82|
|52 Week Range||30.90 - 36.82|
|PE Ratio (TTM)||22.65|
|Forward Dividend & Yield||1.28 (3.58%)|
|1y Target Est||N/A|
Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.
Roche recently sued Pfizer to block the latter’s biosimilar (generic version) for Herceptin- a cancer biologic that earned $2.5 billion in sales in the U.S. for Roche in 2016. The fight is unlikely to stop there for Roche, as it has a lot more at stake.
Spark Therapeutics shares have plunged today, falling $27, or 37%, to $44.03 after the gene-therapy company released disappointing results for its treatment for hemophilia A at the American Society of Hematology’s annual meeting in Atlanta. The data on four patients in a phase 1/2 clinical trial showed some variability in the expression of Factor VIII, the clotting protein either missing or existing at very low levels in hemophilia A patients. It appears that Spark (ONCE) has lost the lead in developing a hemophilia A treatment to BioMarin Pharmaceutical (BMRN), a much larger biotechnology company that reported consistent levels of Factor VIII expression at the ASH conference in a phase 1/2 trial for its gene-therapy treatment.
Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.
Today, the generic drug giant announced the exclusive launch of its generic Viagra (sildenafil citrate) tablets in the U.S. Viagra (generic name sildenafil) is a drug used in the treatment of erectile dysfunction, also known as impotence. Introduced by Pfizer Inc. in March 1998, Viagra has generated about $1.4 billion in the U.S., according to IMS data as of August 2017.
Blueprint unveiled new data from its ongoing Phase 1 study of avapritinib in advanced systemic mastocytosis at the 59th American Society of Hematology Annual Meeting.
Shares of Teva Pharmaceutical Industries Ltd. rose 0.4% in morning trade Monday, after the drug maker announced the exclusive launch of its generic Viagra tablets in the U.S. The company said it will offer ...
Patients with advanced breast cancer tied to an inherited gene mutation who were treated with an experimental Pfizer Inc drug went about three months longer before their disease worsened than those who received chemotherapy in a late stage study, according to data released on Friday. The drug, talazoparib, a once daily pill that Pfizer acquired with its $14 billion purchase of Medivation, belongs to a class of medicines called PARP inhibitors that may induce tumor cell death. Patients in the Phase III study had mutations of the BRCA1/2 genes, the type of mutation that led actress Angelina Jolie to have preventive breast removal surgery.
In 3Q17, Eli Lilly’s (LLY) Humalog generated revenues of $696.2 million, ~9% growth on year-over-year (or YoY) basis and 3% growth on a quarter-over-quarter basis.
Allergan reported EPS of $4.15 on revenues of $4.03 billion in 3Q17, which was 11.4% higher YoY, compared with its revenues of $3.62 billion in 3Q16.
Pfizer (PFE) releases impressive new data of a post-hoc analysis from a phase III study on the combo therapy of Ibrance and Femara for the first-line treatment of ER+, HER2- metastatic breast cancer.